Johnson & Johnson (JNJ) PT Set at $134.00 by Goldman Sachs

Johnson & Johnson (NYSE:JNJ) has been given a $134.00 price target by equities researchers at Goldman Sachs in a research report issued on Tuesday. The brokerage presently has a “sell” rating on the stock. Goldman Sachs’ target price indicates a potential upside of 2.97% from the company’s previous close.

JNJ has been the topic of a number of other research reports. Zacks Investment Research downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Monday, April 9th. Jefferies Group set a $153.00 price objective on shares of Johnson & Johnson and gave the company a “buy” rating in a research note on Friday. Vetr lowered shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating and set a $124.55 price objective for the company. in a research note on Monday, March 26th. Credit Suisse Group set a $154.00 price objective on shares of Johnson & Johnson and gave the company a “hold” rating in a research note on Monday, January 22nd. Finally, Royal Bank of Canada reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, January 9th. Five analysts have rated the stock with a sell rating, nine have assigned a hold rating and eight have given a buy rating to the company’s stock. Johnson & Johnson presently has an average rating of “Hold” and a consensus target price of $144.23.

How to Become a New Pot Stock Millionaire

NYSE:JNJ traded down $1.62 during mid-day trading on Tuesday, hitting $130.14. 5,578,553 shares of the company’s stock were exchanged, compared to its average volume of 7,869,039. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.41 and a quick ratio of 1.12. Johnson & Johnson has a fifty-two week low of $120.95 and a fifty-two week high of $148.32. The company has a market cap of $350,440.66, a PE ratio of 17.83, a P/E/G ratio of 2.08 and a beta of 0.74.



Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, April 17th. The company reported $2.06 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.01 by $0.05. The firm had revenue of $20.01 billion for the quarter, compared to the consensus estimate of $19.50 billion. Johnson & Johnson had a net margin of 1.70% and a return on equity of 29.00%. The company’s revenue for the quarter was up 12.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.83 EPS. equities research analysts expect that Johnson & Johnson will post 8.11 EPS for the current year.

In other news, VP Paulus Stoffels sold 155,342 shares of the company’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $129.86, for a total value of $20,172,712.12. Following the completion of the sale, the vice president now owns 357,906 shares in the company, valued at approximately $46,477,673.16. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.22% of the company’s stock.

Several large investors have recently modified their holdings of JNJ. Goodman Financial Corp bought a new position in shares of Johnson & Johnson in the fourth quarter worth approximately $104,000. Harding Loevner LP bought a new position in Johnson & Johnson during the second quarter valued at approximately $106,000. Stelac Advisory Services LLC bought a new position in Johnson & Johnson during the fourth quarter valued at approximately $108,000. IHT Wealth Management LLC grew its position in Johnson & Johnson by 46.4% during the second quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock valued at $122,000 after acquiring an additional 3,467 shares during the last quarter. Finally, Mountain Capital Investment Advisors Inc bought a new position in Johnson & Johnson during the second quarter valued at approximately $124,000. 67.23% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Johnson & Johnson (JNJ) PT Set at $134.00 by Goldman Sachs” was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at https://stocknewstimes.com/2018/04/17/johnson-johnson-jnj-pt-set-at-134-00-by-goldman-sachs.html.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply